Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes

Document Type

Article

Publication Date

4-1-2017

Publication Title

Current medical research and opinion

Abstract

Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Glucose control: Recently approved in the United States and in Europe for use in type 1 and type 2 diabetes, Gla-300 has a more constant and evenly distributed glucose-lowering effect compared with Gla-100, with a duration of action beyond 24 hours and lower within-day and between-day intra-individual variability in blood glucose levels. These benefits translate into predictable and sustained glucose control from a once-daily injection, with potential for fewer hypoglycemia episodes and less weight gain.

CASE STUDIES: Case studies are presented to highlight the potential clinical benefits and considerations associated with initiating treatment with Gla-300 in people with type 1 and type 2 diabetes.

Medical Subject Headings

Diabetes Mellitus; Drug Monitoring; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Treatment Outcome

PubMed ID

28132529

Volume

33

Issue

4

First Page

785

Last Page

793

Find It @ Sladen

Share

COinS